Sign in

    Malcolm Kuno

    Research Analyst at JPMorgan Chase & Co.

    Malcolm Kuno is an Analyst in the Research Division at JPMorgan Chase & Co., specializing in healthcare and biotechnology sector equity research. He has been involved in covering and analyzing companies such as CytomX Therapeutics, Rapt Therapeutics, BridgeBio Pharma, Elevation Oncology, and ProKidney Corp, working alongside senior biotech analysts on high-profile research teams. With experience presenting and moderating at major industry conferences like the JPMorgan Healthcare Conference, Kuno has contributed to research efforts and investor presentations under senior analysts such as Anupam Rama. He joined JPMorgan in the early 2020s, following earlier analytical roles, and maintains active credentials as an equity research professional with participation in FINRA-registered activities.

    Malcolm Kuno's questions to Ultragenyx Pharmaceutical (RARE) leadership

    Malcolm Kuno's questions to Ultragenyx Pharmaceutical (RARE) leadership • Q3 2024

    Question

    Malcolm Kuno, on for Anupam Rama, asked what specific data points investors should focus on in the upcoming Angelman syndrome program updates at medical conferences.

    Answer

    CEO Emil Kakkis stated the update will feature longer-term data through day 338 for the expansion cohort, which aligns with the Phase 3 trial's length. He added that they will also present data showing that using raw scores versus GSV scores for analysis does not impact the study's power, addressing a key investor question, and will provide a general safety update.

    Ask Fintool Equity Research AI